Boston, MA · Founded 2022 · Privately Held (backing)
Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. Syntis Bio is based in Boston, MA and was founded in 2022. It was valued at $67 million at its early-stage round in Jun 2025, the last priced event on record. It has raised $48.4 million across 3 recorded rounds; the latest was a $25 million early-stage round in Jun 2025.
PMV mark · valuation
$67.0M
Oct 2026
Priced at
its early-stage round
Jun 2025
Total raised
$48.4M
Last round
Early Stage VC
Jun 2025
No prints on record
No secondary trades in Syntis Bio shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Syntis Bio with a free account
·The complete investor list: 12 names
·Watch Syntis Bio: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Syntis Bio stock.
